Kala Pharmaceuticals Inc. said the underwriters of its offering exercised their option in full to buy an additional 1,125,000 shares, thereby taking the total gross proceeds to $71.2 million.

The Waltham, Mass.-based company offered a total of 8,625,000 shares at $8.25 apiece.

J.P. Morgan, Bank of America Merrill Lynch and Jefferies acted as joint book-running managers, while Cantor Fitzgerald & Co. served as lead manager for the offering. Wedbush PacGrow and Oppenheimer & Co. Inc. acted as co-managers.

The company develops treatments using its proprietary mucus-penetrating particle technology, currently targeting eye diseases.